# Bayer account plan

> Bayer is a German life science group in crop science, pharmaceuticals and consumer health, with 2025 sales of €45,575 million and 88,078 employees.

## At a glance

Bayer, headquartered in Leverkusen, is a life science group with three divisions: Crop Science (seeds, traits, crop protection and digital farming), Pharmaceuticals (prescription medicines and radiology) and Consumer Health (nonprescription self-care brands). It had 272 consolidated companies in approximately 80 countries and 88,078 employees (FTE) at Dec. 31, 2025. FY2025 sales were €45,575 million, EBITDA before special items €9,669 million (margin 21.2%) and core EPS €4.91, while net income was minus €3,620 million after litigation charges. Bayer AG is listed and run by CEO Bill Anderson, whose contract runs to March 31, 2029.

## Business units

- **Crop Science** (about 47% of FY2025 Group sales (€21,622 million, computed)): Seeds and traits (DEKALB corn, Intacta soybeans), chemical and biological crop protection (Roundup) and digital farming, sold via wholesalers, retailers and direct to farmers. Margin was 19.4% in 2025 but rose to 31.4% in H1 2026 on the Corteva licensing resolution, the return of the dicamba label and efficiency programs. Led by Rodrigo Santos.
- **Pharmaceuticals** (about 39% of FY2025 Group sales (€17,829 million, computed)): Prescription medicines in cardiology, women's healthcare, oncology, hematology and ophthalmology, plus radiology. Nubeqa (€2,385 million, +62.4%) and Kerendia (€829 million, +88.0%) offset Xarelto generics and Eylea declines. Led by Stefan Oelrich.
- **Consumer Health** (about 13% of FY2025 Group sales (€5,802 million, computed)): Nonprescription brands such as Bepanthen, Canesten, Claritin, MiraLAX, Aleve and Aspirin, sold through pharmacies, supermarkets and online. Sales were flat in 2025 amid weak US and China markets and grew 3.5% in H1 2026. Led by Julio Triana.

## Strategic priorities

- **Five turnaround priorities**: The CEO lists pharma pipeline, Crop Science profitability, debt, litigation and bureaucracy as "no-regret moves" whether Bayer stays together or does something different with a division.
- **Contain glyphosate litigation**: A proposed US class settlement of up to US$7.25 billion over up to 21 years and the June 2026 Supreme Court Durnell ruling on FIFRA preemption aim to significantly contain litigation by the end of 2026.
- **Crop Science Five-Year Framework**: Return to mid-20% EBITDA margins and launch ten blockbusters with sales over €500 million each within ten years, with new value pools in biologicals, hybrid wheat and biofuels.
- **Pharma growth drivers**: Launch Nubeqa, Kerendia, Beyonttra, Lynkuet and asundexian, which is being readied for market in Q4 2026, and grow the US business.
- **Dynamic Shared Ownership and AI**: Up to six organizational layers removed, management cut by roughly two-thirds and 90-day cycles; agentic AI is the next lever for effectiveness.
- **Debt reduction**: The new CFO's priorities are to strengthen the balance sheet and improve productivity and cash generation; net financial debt guidance for 2026 is €29.0 to €30.0 billion.

## Latest results

In H1 2026 sales were €24,277 million, +3.3% currency and portfolio adjusted, and EBITDA before special items rose 6.6% to €6,597 million (margin 27.2%), with core EPS of €3.66. Crop Science led, with EBITDA before special items up 20.5% to €3,916 million, while Pharmaceuticals was flat as Xarelto (–41.4%) and Eylea (–26.8%) fell. Free cash flow was minus €2,691 million due to litigation payouts, and net financial debt reached €33,647 million at June 30, 2026. The 2026 guidance was confirmed: currency-adjusted sales €45 to €47 billion, EBITDA before special items €9.6 to €10.1 billion and core EPS €4.30 to €4.80.

## Investments and deals

- **Apollo minority investment**: In July 2026 Apollo-managed funds agreed a €3.0 billion minority investment in a new entity holding the long-acting reversible contraceptives business; Bayer keeps control.
- **Capital expenditure**: Capex was €2,487 million in 2025, including R&D expansion in Monheim, fungicide capacity in Dormagen, cell and gene therapy facilities and a new Consumer Health site in Qidong, China.
- **Pharma deals**: Acquisition of Perfuse Therapeutics (upfront about €260 million) for a glaucoma and diabetic retinopathy implant, cardiac amyloidosis radiotracers, and an AI drug discovery collaboration with Iambic.
- **Crop Science partnerships**: An alliance with bp on camelina for biofuels and an exclusive hybrid wheat licence with RAGT, expected to bring annual revenues of up to €1 billion by the mid-2040s.
- **Divestments and Ruveon**: Avelox was sold for €250 million and the US glyphosate business was consolidated into Ruveon LLC.

## Challenges and risks

- **Litigation payouts**: About €5 billion of litigation payouts are expected in 2026, driving free cash flow guidance of minus €2.5 to minus €1.5 billion; PCB cases continue.
- **Loss of exclusivity**: Xarelto and Eylea active-ingredient protection has expired in key markets, with Xarelto down 31.6% in 2025.
- **Crop protection pressure**: Generic price pressure, possible restrictions on crop protection actives and the dicamba label vacatur weighed on Crop Science.
- **Pharmaceutical pricing**: Stricter US pricing actions, including most-favoured-nation pricing, and China's volume-based procurement are rated risks.
- **Credit ratings**: Ratings are BBB / Baa2 / BBB; Moody's moved to stable in July 2026 while S&P and Fitch remain negative.

## What leadership says

> "If dynamic shared ownership is our opportunity to make the enterprise more entrepreneurial, agentic artificial intelligence is our chance to make the organization more effective" — Bill Anderson, CEO, Annual Stockholders' Meeting address, April 24, 2026

> "We're definitely in a better position now than we've been at any point in the last few years to make strategic choices" — Bill Anderson, CEO, Q2 2026 earnings call, August 4, 2026

> "To continue to strengthen the balance sheet, to improve productivity and cash generation, and to create flexibility to invest for future growth." — Judith Hartmann, CFO, Q2 2026 earnings call, August 4, 2026

> "We're not going to do major acquisitions." — Stefan Oelrich, Head of Pharmaceuticals, Q2 2026 earnings call, August 4, 2026


## Where a supplier can help

- **Agentic AI and IT infrastructure**: Tied to the Dynamic Shared Ownership and AI priority: Bayer is investing in IT infrastructure and data for agentic AI.
- **Productivity and cost tools**: Tied to the debt reduction priority and the Crop Science Five-Year Framework: offers that lower cost of goods and overhead.
- **Launch commercial support**: Tied to the pharma growth drivers: market access, medical affairs and launch services for asundexian, Lynkuet and Kerendia.
- **Agricultural innovation partners**: Tied to Crop Science partnerships: biologicals, hybrid wheat, biofuels and digital farming collaborations.
- **Regulatory and legal operations**: Tied to the litigation challenge: claims administration, regulatory science and legal operations support.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Bayer Annual Report 2025](https://www.bayer.com/sites/default/files/2026-03/bayer-annual-report-2025.pdf)

Annual report · 2026-03-04

- Bayer is a life science group (HQ Leverkusen) with three divisions, Crop Science, Pharmaceuticals and Consumer Health, under the mission "Health for all, Hunger for none"; 88,078 employees (FTE) at Dec. 31, 2025, 272 consolidated companies in approximately 80 countries.
- FY2025: sales €45,575 million (Fx & portfolio adj. +1.1%, reported –2.2%, currency headwind €1,742 million); EBITDA before special items €9,669 million (–4.5%, margin 21.2%); core EPS €4.91 (–2.8%); free cash flow €2,084 million; net financial debt cut to €29,843 million; net income minus €3,620 million after litigation charges; dividend kept at €0.11.
- Crop Science €21,622 million sales (+1.1% Fx & p adj., margin 19.4%), driven by Corn Seed & Traits (+13.2%) against dicamba label vacatur and the Movento registration expiry; Five-Year Framework targets a return to mid-20% EBITDA margins and ten blockbusters (each over €500 million) in ten years.
- Pharmaceuticals €17,829 million (+1.7%, margin 25.4%): Nubeqa €2,385 million (+62.4%) and Kerendia €829 million (+88.0%) offset Xarelto (–31.6%) and Eylea (–3.7%); launches of Lynkuet, Beyonttra and Hyrnuo; asundexian positive Phase III in secondary stroke prevention.
- Consumer Health €5,802 million (–0.1%, margin 23.1%): growth in Digestive Health, Dermatology and Pain & Cardio, declines in Nutritionals and Allergy & Cold amid weak US and China markets.
- Glyphosate: in February 2026 Monsanto announced a proposed US nationwide class settlement (declining capped payments up to US$7.25 billion over up to 21 years); the US Supreme Court agreed in January 2026 to review the Durnell preemption case; glyphosate provisions and liabilities US$11.3 billion (€9.6 billion) at year end.
- 2026 outlook (currency-adjusted): sales €45 to €47 billion, EBITDA before special items €9.6 to €10.1 billion, core EPS €4.30 to €4.80 (new method), free cash flow –€2.5 to –€1.5 billion due to approximately €5 billion of litigation payouts, net financial debt €32.0 to €33.0 billion.
- Operating model "Dynamic Shared Ownership": up to six organizational layers removed, management positions cut by roughly two-thirds, 90-day cycles; ratings BBB / Baa2 / BBB, all with negative outlook.

### [Bayer Half-Year Financial Report Q2 2026](https://bag-p-001.sitecorecontenthub.cloud/api/public/content/bayer-half-year-financial-report-q2-2026-6af8ff27ca524ff4ba8f5418fe3609eb?v=b3268919)

Interim report · 2026-08-04

- Q2 2026 sales €10,872 million (Fx & p adj. +2.2%); H1 sales €24,277 million (+3.3% Fx & p adj., reported –0.8%) with a €949 million negative currency effect.
- H1 EBITDA before special items €6,597 million (+6.6%, margin 27.2%); H1 core EPS €3.66 (+3.4%), Q2 core EPS €0.95 (–16.7%); H1 net income €2,982 million.
- Crop Science led: H1 sales +5.5% to €12,468 million and EBITDA before special items +20.5% to €3,916 million (margin 31.4%), helped by a licensing resolution with Corteva, the return of the dicamba label and efficiency programs.
- Pharmaceuticals flat (H1 €8,707 million, +0.2%): Nubeqa €1,629 million (+60.6%) and Kerendia €603 million (+83.5%) offset Xarelto (–41.4%) and Eylea (–26.8%); margin 26.4%. Consumer Health H1 +3.5% to €2,936 million, margin 22.3%.
- Litigation: in June 2026 the US Supreme Court ruled 7:2 in Durnell that FIFRA preempts state failure-to-warn claims; H1 litigation payouts €2,246 million, including €432 million paid into the class settlement trust.
- H1 free cash flow minus €2,691 million; net financial debt €33,647 million at June 30, 2026.
- July 2026: €3.0 billion Apollo minority investment in a new entity holding the long-acting reversible contraceptives (LARC) business; US$5.0 billion bond issue; US glyphosate business consolidated into Ruveon LLC.
- Guidance confirmed (currency-adjusted sales €45 to €47 billion, EBITDA before special items €9.6 to €10.1 billion, core EPS €4.30 to €4.80); net financial debt guidance lowered to €29.0 to €30.0 billion.

### [Bayer Q2 2026 Earnings Call (investor video call)](https://allmind.ai/earnings/event/2950436)

Executive talk · Bill Anderson, Chairman of the Board of Management (CEO) · 2026-08-04

- Bill Anderson: "operationally, we are on track for the year"; H1 sales EUR 24 billion, up 3% currency and portfolio adjusted, core EPS EUR 3.66, free cash flow EUR -2.7 billion because of litigation payouts.
- Litigation: Anderson called the Supreme Court's 25 June decision a "landmark ruling"; the class settlement is "moving ahead", with the final approval hearing in Missouri scheduled for 19 August.
- Group structure: Bayer is "in a better position now than we've been at any point in the last few years to make strategic choices", but for now will keep driving its five priorities, which he calls "no-regret moves" whether Bayer stays together or does "something different with a division".
- New CFO Judith Hartmann: priorities are to "strengthen the balance sheet", improve productivity and cash generation and create flexibility to invest; the EUR 3 billion Apollo investment and a $5 billion bond issue; net debt guidance now EUR 29 to 30 billion; dividend policy to be addressed with full-year results in February.
- Crop Science: H1 margin of 31.4% expected to moderate in H2; soybean growth of nearly 70% year to date, 13% excluding licensing income; glyphosate is 10% of total sales and runs as a separate entity (Ruveon) in the US.
- Pharma (Stefan Oelrich): asundexian is being readied for the market in Q4, priced first in the US and China; Eylea 8 mg is around 55% of franchise sales in Q2, on track for about 70% by year end; "We're not going to do major acquisitions."
- Anderson wants to spend freed-up time on the new operating model and its "intersection of that with AI to more rapidly reinvent every part of our business".

### [Address by Bill Anderson, Annual Stockholders' Meeting 2026](https://www.bayer.com/media/2026-1502e)

Executive talk · Bill Anderson, Chairman of the Board of Management (CEO) · 2026-04-24

- Bill Anderson's address to the Annual Stockholders' Meeting, April 24, 2026: the March 2024 agenda was to "Revitalize the pipeline. Reduce debt. Significantly contain litigation." and tackle bureaucracy; two years on, "The work isn't complete. Yet."
- 2025: sales 45.6 billion euros, core EPS 4.91 euros, free cash flow 2.1 billion euros, net financial debt reduced to 29.8 billion euros; net debt expected to rise in 2026 on litigation expenses.
- 2026: core EPS before FX roughly in line with last year and negative free cash flow from litigation payouts; minimum dividend proposed again, with capital allocation and dividend policy under review.
- Pharma: Nubeqa and Kerendia grew a combined 68 percent; Beyonttra given to half of newly diagnosed patients in Germany one year after launch; Lynkuet launching in the US, then the EU; asundexian results "outstanding".
- Crop Science: performance improvement program, portfolio and footprint rationalized, reshaping crop protection around higher-margin molecules; Plenexos launched in Colombia, Brazil next; big innovation plans "really take off in 2027 and beyond".
- Litigation: Monsanto class settlement announced in February with preliminary approval in early March; US Supreme Court oral arguments scheduled for the following Monday; Kentucky passed a law protecting farmers' access to regulated crop protection products.
- Operating model: 90-day cycles, layers roughly halved, management cut by two thirds; agentic AI seen as "our chance to make the organization more effective".

## Questions about Bayer

### What does Bayer do?

Bayer is a life science company with three divisions: Crop Science (seeds, traits and crop protection), Pharmaceuticals (prescription medicines and radiology) and Consumer Health (nonprescription self-care products).

### What is Bayer's revenue?

Bayer's sales were €45,575 million in 2025; for 2026 it guides currency-adjusted sales of €45 to €47 billion.

### How many employees does Bayer have?

Bayer had 88,078 employees (FTE) at Dec. 31, 2025 and 87,830 at June 30, 2026.

### Who leads Bayer?

Bill Anderson is CEO (Chairman of the Board of Management); Judith Hartmann has been CFO since June 1, 2026.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
